Oxbryta Lawsuit
The Oxbryta lawsuits are a series of legal actions initiated against Pfizer and its subsidiary, Global Blood Therapeutics, following the September 2024 global withdrawal of Oxbryta (voxelotor), a medication developed to treat sickle cell disease (SCD). These lawsuits allege that the companies failed to adequately warn patients and healthcare providers about the drug's potential risks, which include serious complications and fatalities.
Background on Oxbryta
Oxbryta was approved by the U.S. Food and Drug Administration (FDA) in 2019 to treat SCD by inhibiting hemoglobin polymerization, thereby reducing red blood cell sickling. Initially hailed as a breakthrough, subsequent clinical trials and post-marketing data revealed an increased risk of vaso-occlusive crises (VOCs) and deaths among patients taking the drug. In response, Pfizer voluntarily withdrew Oxbryta from the market in September 2024, citing that the drug's risks outweighed its benefits.
Potential Compensation for Plaintiffs
Individuals who have suffered adverse effects from Oxbryta may be eligible for compensation
-
Medical expenses related to treatment and hospitalization.
-
Lost wages due to inability to work.
-
Pain and suffering endured from complications
-
Wrongful death claims for families of deceased patients.